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Abstract 
After metabolic reprogramming, many cancer cells 
become glutamine addicted, that is, they depend on 
a high consumption of this amino acid for their 
survival and proliferation. Glutaminase catalyzes 
the stoichiometric conversion of L-glutamine to L-
glutamate and ammonium ions, the first step of 
glutaminolysis. GLS gene encodes two isoforms, 
known as kidney-type glutaminase (KGA) and 
glutaminase C (GAC). Upregulation of GLS is a 
common feature of many tumors and, in recent 
years, this enzyme and its interacting partners have 
attracted much attention as potential new targets for 
cancer therapy. Considerable effort is being devoted 
towards the development of small-molecule 
inhibitors of GLS. 
Keywords 
Glutaminase, glutamine addiction, anticancer 
therapy, BPTES, CB-839, compound 968, breast 
cancer, colorectal cancer, glioblastoma, 
hepatocellular carcinoma, leukemia, lung cancer, 
melanoma, ovarian cancer, prostate cancer. 
Identity 
Other names: GA; KGA; GAC; PAG 
HGNC (Hugo): GLS (Glutaminase) 
Location: 2q32.2 
Figure 1. Genomic structure of human glutaminase GLS gene and alternative transcripts KGA and GAC. Introns are depicted as 
solid light blue lines and exons as numbered dark blue boxes. Dashed red or dotted black lines indicate the exons involved in the 
generation of KGA and GAC transcripts, respectively (Campos-Sandoval et al., 2015). 










Human GLS gene is located on chromosome 2 
(Aledo et al., 2000). It is composed of 19 exons and 
spans approximately 82 kb (Porter et al., 2002). The 
gene resides on the forward strand. It starts at 
190880821 and ends at 190965552 from pter 
(NCBI, GeneID 2744). 
Transcription 
Two different transcripts coding for functional 
proteins arise from this gene by a mechanism of 
alternative splicing: a long KGA transcript, first 
isolated from brain, which contains exons 1-14 and 
16-19 of the GLS gene (Nagase et al., 1998; 
Holcomb et al., 2000; Porter et al., 2002), and a 
shorter GAC transcript, formed by the first 15 
exons and originally described in human colon 
cancer cells (Elgadi et al., 1999). A third transcript 
has been found in heart and skeletal muscle that 
codes for a much shorter protein (GAM) with no 
measurable catalytic activity (Elgadi et al., 1999).  
Several mechanisms regulate glutaminase 
expression. The first one to be described is based on 
the presence of AU-rich pH-responsive instability 
elements within the 3'-nontranslated region of GLS 
mRNA. These elements are implicated in the rapid 
turnover of mRNAs by exonucleolytic degradation. 
The onset of metabolic acidosis results in the 
increased binding activity of a RNA-binding 
protein CRYZ (identified as ζ-crystallin/NADPH 
quinone reductase) with high affinity for the pH-
responsive elements, that selectively stabilizes GLS 
mRNA (Hansen et al., 1996; Tang and Curthoys, 
2001). Upregulation of GAC by the long non-
coding RNA (lncRNA) colon cancer-associated 
transcript 2 (CCAT2) has recently been reported in 
colon cancer. This lncRNA interacts with the 
cleavage factor I (CFIm) complex in an allele-
specific manner and select the poly(A) site within 
14th intron of GLS pre-mRNA, resulting in the 
preferential splicing of GAC isoform (Redis et al., 
2016). MicroRNAs (miRNAs) are also implicated 
in GLS expression. Through downregulation of 
MIR23A / MIR23B, which target GLS mRNA, the 
oncogenic transcription factor MYC (v?myc 
myelocytomatosis viral oncogene homolog) 
indirectly relieves repression of GLS in lymphoma 
and prostate cancer cells (Gao et al., 2009).  
The MTOR complex 1/ RPS6KB1 
(mTORC1/S6K1 (mammalian target of rapamycin 
complex 1/ribosomal protein S6 kinase beta-1)) 
signaling pathway positively regulates GLS 
expression by enhancing the translation efficiency 
of Myc mRNA.  
After inhibition of mTORC1 with rapamycin, an 
increase in miR-23a/b levels was observed (Csibi et 
al., 2014).  
The activation of RELA (v-rel avian 
reticuloendotheliosis viral oncogene homolog A, 
also known as p65), a member of nuclear factor 
kappa B (NF-kB) family, also decreases miR-23a 
expression in leukemic cells, inducing GLS 
expression (Rathore et al., 2012).  
Another transcription factor, JUN (v-jun avian 
sarcoma virus 17 oncogene homolog), when 
activated downstream of oncogenic Rho GTPase 
signaling, increases GLS expression in breast 
cancer cells by direct binding to its gene promoter 
(Lukey et al., 2016). After being activated by 
transforming growth factor (TGF)-β and Wnt 
(Wingless-type MMTV integration site family)-3a, 
the homeodomain transcription factor DLX2 
(distal-less homeobox-2), involved in embryonic 
and tumor development, also upregulates GLS 
expression (Lee SY et al., 2016a).  
Transcription of GLS gene is also activated in HIV-
1 infected cells by interferon (IFN)-α through signal 
transducer and activator of transcription 1 (STAT1) 
phosphorylation, leading to glutamate 
overproduction (Zhao et al., 2012).  
Retinoblastoma protein (RB1), a tumor suppressor 
that modulates cell cycle checkpoints, also regulates 
glutamine metabolism.  
Deletion of RB family revealed an increase in GLS 
protein and activity (Reynolds et al., 2014). 
Protein 
Note 
In recent years, considerable effort is being devoted 
towards the development of small-molecule 
inhibitors that target GLS and its interacting 
partners (Katt et al., 2017; Matés et al., 2018). 
Structural information of truncated or full 
recombinant human GLS complexed with substrate 
(glutamine), product (glutamate), the allosteric 
activator phosphate or inhibitors is now available 
(DelaBarre et al., 2011; Cassago et al., 2012; 
Thangavelu et al., 2012; Pasquali et al., 2017). 
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Figure 2. Schematic diagram of GLS isoforms showing the localization of predicted domains and motifs by sequence analysis 




A 10000-fold purification of glutaminase (KGA) 
from pig kidney was achieved by Kvamme et al. 
(1970) using alternative solubilization and 
precipitacion steps, based on its property to 
aggregate in phosphate-borate buffers and to 
disaggregate in Tris-HCl buffers. KGA may appear 
as three different forms: a dimeric and inactive 
form in Tris-HCl buffer; a tetrameric and active 
form after combination of two dimers when 
dialyzed against phosphate buffer; and a polymeric 
form with mass higher that 2000 kDa in the 
presence of phosphate-borate buffer. These 
polymers consist of double-stranded helices 
(Kvamme at al., 1970; Olsen et al., 1970; Godfrey 
et al., 1977).  
Structure:  
KGA transcript (ORF: 2010 nt) codes a 669-
residues protein, with a predicted molecular mass of 
73.5 kDa. GAC transcript (ORF: 1797 nt) codes a 
598-residues protein, with a predicted molecular 
mass of 65.5 kDa. Both precursors are identical in 
almost all their primary structure (exons 1-14, 
residues 1-550), except in the C-terminal region 
(residues 551-669 for KGA; 551-598 for GAC). 
They are composed of a N-terminal domain folded 
into an EF-hand-like four-helix bundle (Pasquali et 
al., 2017) and a central glutaminase domain from 
residues 220 to 530, which belongs to the beta 
lactamase/transpeptidase-like superfamily and 
contains the catalytic active site (Thangavelu et al., 
2012). In addition, the C-terminal region of KGA 
possesses three ankyrin repeats, also present in 
GLS2 proteins but not in the GAC isoform 
(Pasquali et al., 2017), and KEN (Lys-Glu-Asn) and 
D (destruction) boxes. The ankyrin repeats are 
protein-protein interaction modules of 33 residues 
that have been found in many important proteins 
such as transcriptional factors, cell cycle regulators, 
cytoskeletal organizers, etc. (Sedgwick and 
Smerdon, 1999; Mosavi et al., 2004). Both KEN 
and D boxes are recognized by the ubiquitin ligase 
APC/C-Cdh1 (anaphase-promoting 
complex/cyclosome-Cdh1) which targets KGA for 
degradation by the proteasome (Colombo et al., 
2011). The GLS precursor also has a putative N-
terminal mitochondrial targeting sequence of 16 
residues (Shapiro et al., 1991). The Curthoys 
laboratory, in a series of studies on the biosynthesis 
and processing of the rat KGA, found that the 74 
kDa precursor is processed in the mitochondria by a 
matrix processing peptidase to yield two subunits of 
66 (cleavage site at residue 72) and 68 kDa with a 
3:1 stoichiometry (Perera et al., 1990; Srinivasan et 
al., 1995). For the human GLS, only a 66 kDa 
protein has been detected when expressed as a 
recombinant protein using the baculovirus 
expression system (Holcomb et al., 2000). As 
previously described for GLS2 (Olalla et al., 2002), 
GLS proteins show a LXXLL motif or nuclear 
receptor box from Leu144 to Leu148 (Cassago et 
al., 2012). In recent years, several groups have 
revealed the structure of GLS based on X-ray 
crystallography. In the asymmetric unit, GLS is 
organized as a tetramer where the monomers 
interact through two sets of interfaces at the 
glutaminase domains. This domain is composed of 
two subdomains: an α/β subdomain that contains 
five-stranded anti-parallel β-sheet surrounded by 
several α-helices, and an α-helical subdomain with 
seven α-helices. Two GLS monomers are joined by 
a long interface of their respective α-helical 
subdomains to form an inactive dimer. Two 
opposing dimers then associate by a short interface 
involving two pairs of equivalent anti-parallel α-
helices (α-13) at the α /β subdomains, which come 
into contact by hydrophobic interactions. 
(DeLaBarre et al., 2011; Cassago et al., 2012; 
Thangavelu et al, 2012). When a phenylalanine 
residue (Phe394 in the mouse GAC) in the short 
dimer interface was mutated to a serine one, GAC 
persisted as an inactive dimer even at high 
concentrations of phosphate (Cassago et al., 2012). 
The presence of salt bridges between Asp391 and 
Lys401 at both ends of the pairing helices further 
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stabilizes the quaternary structure. The replacement 
of Asp391 by a lysine residue had a similar effect to 
that caused by the phenylalanine substitution (Li et 
al., 2016). 
Kinetic properties:  
Both GLS isoforms require a polyvalent anion to be 
active. A decade after Krebs (1935) proposed the 
existence of two different types of glutaminase, one 
of them (GLS) strongly inhibited by the product 
glutamic acid, Carter and Greenstein (1947) 
observed an accelerated deamidation of glutamine 
in aqueous rat-liver extracts in the presence of 
phosphate, arsenate or sulfate and suggested that 
this effect could be due to an augmentation of the 
activity of glutaminase enzyme. Errera and 
Greenstein (1949) characterized it as phosphate-
activated glutaminase. It was later found that 
phosphate induced the association of catalytically 
inactive dimers into active tetramers, whereas 
glutamate caused inhibition of glutaminase by 
reversing this process (Godfrey et al., 1977; 
Morehouse and Curthoys, 1981). At a concentration 
of phosphate of 100 mM, tetramerization of 
glutaminase is produced and the enzyme reaches its 
maximum activity. The activation by phosphate is 
sigmoidal, with a K0.5 of 25 mM and a Hill index of 
1.5. When phosphate concentration is increased, 
both the inhibition by glutamate -which is 
competitive with respect to glutamine- and the KM 
for glutamine decrease (Haser et al., 1985). 
Although the activity of the purified enzyme is 
completely dependent on added phosphate, it was 
not known if the high concentration of phosphate 
required for the in vitro reaction could also occur in 
the intracellular site of glutaminase action or 
whether phosphate was the substitute of an 
unknown natural activator (Sayre and Roberts, 
1958). In addition to phosphate, a wide variety of 
physiological compounds (tricarboxylic acids, 
nucleotide triphosphates, acyl-CoA derivatives) 
was found that could act as activators (or inhibitors) 
of glutaminase (O'Donovan and Lotspeich, 1966; 
Weil-Malherbe, 1969; Kvamme and Torgner, 
1975). However, recent X-ray analysis has provided 
support for the candidature of phosphate as a 
relevant in vivo effector: crystal structure of 
glutaminase shows that each GAC monomer 
encloses a single phosphate ion inside its active 
site. It has been proposed that, after binding of 
phosphate, a flexible activation loop located near 
the short dimer interface undergoes a major 
conformational change that stabilizes the active site 
and promotes catalytic turnover (Thangavelu et al., 
2012; Li et al., 2016, Stalnecker et al., 2017).  
Interacting partners:  
The first binding partner for KGA to be described 
was the caytaxin ATCAY (or BNIP-H for BNIP-2 
homology), a protein exclusively expressed in 
neural tissues and encoded by a gene linked to 
Cayman ataxia and dystonia. This protein interacts 
with KGA through a conserved protein-protein 
interaction domain known as the BNIP-2 and 
Cdc42GAP homology (BCH) domain. Caytaxin 
regulates the intracellular localization and activity 
of KGA: it relocalized KGA from cell body to 
neurite terminals and reduced glutamate levels by 
inhibiting its activity (Buschdorf et al., 2006). 
Subsequently, another member of the family of 
BCH-domain containing proteins, PRUNE2 (prune 
homolog 2 with BCH domain, also known as 
BMCC1s), has been shown to directly interact with 
KGA. This protein, associated to microtubules and 
intermediate filaments in astrocytes and neurons, 
may influence import of KGA to mitochondria: 
overexpression of PRUNE2 in mouse neurons led 
to an accumulation of KGA within the cytoplasm 
(Boulay et al., 2013). Very recently, GLS has been 
reported to interact with peroxisome proliferator-
activated receptor gamma ( PPARG) in the nuclei 
of prostate cancer cells, and this interaction 
decreased the nuclear receptor activity (de Guzzi 
Cassago et al., 2018).  
Post-translational modifications:  
Aside from the regulation of GLS gene expression, 
several post-translational modifications affect 
glutaminase activity, with implications for cancer 
cells metabolism. Most of the identified 
modifications correspond to phosphorylation of 
serine, tyrosine and threonine residues (see 
Ascenção et al., 2018 for references), although the 
effect of specific modified residues on GLS activity 
has only recently been studied. Thangavelu et al. 
(2012) revealed that GLS activity in human breast 
adenocarcinoma cells was dependent on 
phosphorylation by epidermal growth factor (EGF) 
via the RAF/MEK/ERK signaling module and was 
completely abolished after treatment with MEK 
inhibitors or co-expression with protein 
phosphatase PP2A. Han et al. (2018) have recently 
found that GLS activity is drastically reduced when 
one of the ten identified phosphorylation sites, 
Ser314 at the glutaminase domain, is mutated to 
alanine. A remarkable reduction in Ser314 
phosphorilation and GLS activity occurs when cell 
lysates of several tumor types are treated with 
alkaline phosphatase. This phosphorylation is 
regulated by the NF-kB-PKCε (PRKCE protein 
kinase C-epsilon) axis. After treatment with a NF-
kB inhibitor, GLS activity could be restored with 
the overexpression of PKCε (Han et al., 2018). In 
contrast, phosphorylation of Ser95 at the N-
terminal domain inhibits GLS activity, but its 
mechanism of deregulation in cancer cells is still 
unknown (Ascenção et al., 2018). Another post-
translational modification that affects GLS activity 
is succinylation. The mitochondrial protein sirtuin 5 
(SIRT5), which removes short-chain acyl moieties 
from lysine residues, regulates GLS activity by 
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reducing its level of succinylation (Polleta et al., 
2015). Acetylation has also been speculated to 
regulate GLS activity. Several lysine residues that 
occur at the α-helix-13 has been identified as sites 
of this modification and their acetylation could 
prevent the formation of active tetramers 
(McDonald et al., 2015). As already mentioned 
above, KGA is also modified by ubiquitination at 
its C-terminal region (Colombo et al., 2011).  
Drug inhibitors:  
The first glutaminase inhibitors to be discovered 
several decades ago were L-glutamine analogs 
isolated from Streptomyces, such as azaserine, 
diazo-O-norleucine (DON) and acivicin. They act 
as irreversible competitive inhibitors for GLS and 
other glutamine-utilizing enzymes: DON binds 
covalently to residue Ser286 at the GLS active site 
(Thangavelu et al., 2014). Although they show a 
significant inhibitory effect on several types of 
tumors in preclinical tests, their pronounced 
toxicity has compromised the therapeutical 
potential of these compounds (Ahluwalia et al., 
1990). The bisthiadiazole derivatives form the 
second important group of inhibitors that was 
described the past few years, the prototype being 
BPTES (Robinson et al., 2007). A more potent 
derivative of BPTES, CB-839 (Gross et al., 2014), 
is being tested in clinical trials (more information at 
http://www.clinicaltrials.gov database). These non-
competitive allosteric inhibitors bind to the 
interface between two dimers, stabilizing an 
inactive tetrameric form of GLS (DeLaBarre et al., 
2011; Thangavelu et al., 2012). The newest 
molecule in this group is the compound 
UPGL00004, with similar binding affinity as CB-
839 but with better microsomal stability (Huang et 
al., 2018). The third group of inhibitors is 
represented by compound 968, a 
benzophenanthridinone that binds to a pocket at the 
interface between two GLS monomers. Unlike 
BPTES, compound 968 preferentially binds to the 
monomeric, inactive form of GLS, and is unable to 
inhibit GLS which has been pre-activated with 
phosphate (Wang et al., 2010; Stalnecker et al., 
2017). Other new GLS inhibitors recently described 
are physapubescin K, (Cheng et al., 2017; Wu et al., 
2017), zaprinast (Elhammali et al., 2014) and 
brachyantheraoside A8 (Li et al., 2017). One 
essential point of GLS inhibition is that these novel 
compounds lack the high degree of toxicity 
observed with glutamine mimetics (Matés et al., 
2018). For an overview of glutaminase inhibitors, 
see: Katt et al., 2017; Song et al., 2018; Wu et al., 
2018; Xu et al, 2018. 
Expression 
The rat KGA isoform has been found in all 
nonhepatic tissues with glutaminase activity, 
including fetal liver (Smith and Watford, 1990; 
Curthoys and Watford, 1995). In human tissues, the 
KGA isoform is expressed in kidney, brain, heart, 
lung and pancreas, but not in skeletal muscle or 
liver (Aledo et al., 2000). The human GAC isoform, 
first described in a cancer cell line, is found 
principally in cardiac muscle and pancreas, at lower 
levels in lung, kidney and placenta, and is not 
detected in brain or liver. (Elgadi et al., 1999). GLS 
proteins are also overexpressed in a wide variety of 
tumors compared to normal tissues, with GAC 
being the predominant isoform in many of them, 
such as breast carcinoma (Elgadi et al., 1999), 
prostate cancer (Gao et al., 2009), non-small cell 
lung cancer (van den Heuvel et al., 2012), leukemia 
(Pérez-Gómez et al., 2005; Matre et al., 2016), 
glioma (Szeliga et al., 2008; Tanaka et al., 2015), 
among others. 
Localisation 
Errera and Greenstein (1949) proposed for the first 
time a mitochondrial location for glutaminase in 
liver, and subsequently different authors 
demonstrated experimentally this location in both 
liver and other organs such as kidney, brain and 
intestine (Klingman and Handler, 1958; Guha, 
1961; Katunuma et al., 1967; Pinkus and 
Windmueller, 1977). However, some authors have 
described a non-mitochondrial cytoplasmic pool of 
glutaminase (Aoki et al., 1991). In a recent study 
with several tumor cell lines, Cassago et al. (2012) 
have reported a cytosolic localization for KGA, 
with only GAC located in mitochondria. These 
findings suggest that the intracellular localization of 
GLS may depend on other factors other than the 
mitochondrial targeting sequence at its N-terminus. 
The sub-mitochondrial location of glutaminase has 
been studied extensively, but it is still a 
controversial issue. Although glutaminase seems to 
be associated with the inner mitochondrial 
membrane (IMM), different orientations of the 
enzyme have been proposed: to both sides of the 
IMM (Kvamme and Olsen, 1979), the 
intermembrane space (c-side) (Kvamme et al., 
1991; Roberg et al., 1995), or the matrix space (m-
side) (Shapiro et al., 1985; Aledo et al., 1997). 
Function 
GLS (E.C. 3.5.1.2.) catalyzes the hydrolytic 
deamidation of L-glutamine to form L-glutamate 
and ammonium, the first step of glutaminolysis. 
This enzyme fulfills essential tasks related to tissue-
specific function. In kidney, glutaminase reaction is 
the initial step in renal ammoniagenesis. As 
mentioned above, GLS is induced through its 
mRNA stabilization in response to metabolic 
acidosis. This results in an increased consumption 
of glutamine extracted from plasma in the proximal 
convolute tubules and the excretion of the generated 
ammonium ions in the urine. The further 
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metabolization of α-ketoglutarate (α-KG) yields 
bicarbonate ions that are transported into blood to 
restore the acid-base balance (Curthoys, 2001). In 
brain, GLS participates in the synthesis and 
recycling of glutamate, the principal excitatory 
neurotransmitter, through the astrocytic-neuronal 
glutamate-glutamine cycle (Nicklas et al., 1987; 
Daikhin and Yudkoff, 2000). Knockout mice for 
the Gls gene die shortly after birth due to impaired 
glutamatergic synaptic function, stressing the 
importance of this enzyme in glutamatergic 
transmission (Masson et al., 2006). Moreover, it has 
been shown that small interfering RNA (siRNA) 
silencing of GLS in neural progenitor cells 
impaired their differentiation, proliferation and 
survival, suggesting a critical role of GLS in 
neurogenesis (Wang et al., 2014).  
Besides its role in normal tissues, glutaminase is 
highly expressed in tumors, where its activity has 
been correlated with malignancy (Knox et al., 1967; 
Linder-Horowitz et al., 1969; Kovacevik and 
McGivan, 1983). Many cancer cells develop what 
has been called "glutamine addiction", a term now 
widely used to reflect the strong dependence for 
this essential nitrogen substrate after metabolic 
reprogramming (Wise et al., 2008). Silencing GLS 
expression by genetic knockdown or inhibiting its 
activity with drug inhibitors reveal the critical role 
of GLS in this addiction. Thus, the specific 
inhibition of GLS by antisense mRNA slowed 
tumor cell growth and induced phenotypic changes 
that made these cells vulnerable to the host's 
immune system (Lobo et al., 2000; Segura et al., 
2001). In addition, GLS enables cancer cells to 
counteract ROS. Glutamate is the precursor of 
glutathione (GSH) and a source or reducing 
equivalents (Hensley et al., 2013). Based on the 
abundant published data on recent years on the role 
of glutaminase in cancer, this enzyme has become a 
potential drug target for therapeutic intervention 
(Matés et al., 2018). 
Implicated in 
Breast cancer 
Breast cancer exhibits subtype-specific phenotype 
of glutamine dependence. Triple negative breast 
cancer (TNBC) showed higher GLS expression 
than ERBB2 (Erb-B2 receptor tyrosine kinase 2)-
positive or luminal subtypes (Kung et al., 2011; 
Kim et al., 2013; Lampa et al., 2017). In a study 
with a panel of breast cancer cell lines, GLS 
inhibitor CB-839 had an anti-proliferative effect on 
TNBC cells but not on estrogen receptor (ER)-
positive or ERBB2-positive cell lines. This effect 
was associated with a significant decrease in both 
glutamine consumption and levels of tricarboxylic 
acid (TCA) cycle intermediates. Sensitivity of 
TNBC cells to CB-839 was correlated with an 
elevated expression of GAC but not KGA (Gross et 
al., 2014). The new GLS inhibitor UPGL00004 had 
a similar effect: it potently inhibited growth in 
TNBC but not in receptor-positive cells (Huang et 
al., 2018). A higher activity of MYC in cells of this 
subtype could maintain expression of GLS (Kung et 
al., 2011). Another effect of GLS inhibition with 
CB-839 was a decrease in MTOR activity. Both 
GLS and mTOR inhibition synergized in TNBC 
cells (Lampa et al., 2017). GLS expression is also 
upregulated by ERBB2 activation. When non-
tumorigenic breast epithelial cells were transformed 
with a constitutive active form of ERBB2, GLS 
mRNA and protein levels were increased through 
activation of NF-kB signaling (Qie et al., 2014). In 
a similar model, knockdown of ephrin-A1, a ligand 
of EPH receptor A2 ( EPHA2), enhanced GLS 
activity through increased levels of Rho GTPase 
and addition of α-KG restored proliferation 
inhibited by compound 968 (Youngblood et al., 
2016). Activation of JUN downstream of Rho 
GTPase signaling led to enhanced glutaminase 
activity (Lukey et al., 2016). An inverse correlation 
between the expression of glutamine synthetase 
(GS, encoded by GLUL) and GLS has been 
observed in luminal and TNBC cells. Moreover, 
GLUL repression led to an increase of GLS mRNA 
levels, and ectopic GDH over-expression reduced 
those levels (Kung et al., 2011). 
Colorectal cancer 
GLS expression is upregulated in colorectal cancer 
(CRC) tissues compared to adjacent normal tissues 
(Huang et al., 2014). In recent years, several 
mechanisms have been described to regulate GLS 
expression in colorectal cancer. Supranutritional 
doses of selenite induced GLS ubiquitination by 
APC/C-CDH1, leading to suppression of 
glutaminolysis and increasing apoptosis in CRC 
cells (Zhao et al., 2017). Heat shock factor 1 ( 
HSF1) participates in malignant transformation in 
many types of tumors. In CRC, high levels of HSF1 
correlates with poor survival. Through inhibition of 
MIR137 which targets GLS, HSF1 stimulates GLS 
expression, resulting in enhanced glutaminolysis 
and MTOR activation (Li et al., 2018). MYCN 
downstream regulated gene 2 ( NDRG2), a tumor 
suppressor, has been shown to regulate GLS 
expression. When overexpressed in CRC cells, 
NDRG2 inhibited glucolysis and glutaminolysis via 
repression of MYC. (Xu et al., 2015). GLS 
expression seems to be also regulated by TP53. 
Costunolide, a natural sesquiterpene lactone with 
antitumoral activity, stimulated the nuclear 
translocation of TP53 and downregulated GLS 
mRNA and protein levels, resulting in lower 
intracellular levels of glutamate and α-KG. 
Treatment with a TP53 inhibitor rescued GLS 
expression, indicating that activation of TP53 was 
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required for costunolide to downregulate GLS 
expression in CRC cells (Hu et al., 2018). 
Glioblastoma 
The effect of glutaminase inhibition on 
glioblastoma (GBM) have been addressed in 
isocitrate dehydrogenase ( IDH1 or IDH2) wild 
type or mutant cell lines. GBM cells that harbour 
IDH mutations acumulate 2-hydroxyglutarate (2-
HG), an oncometabolite primarily derived from 
glutamine (Dang et al., 2009). When compared to 
IDH wild type cells, IDH mutant cells treated with 
the GLS inhibitor BPTES showed a slower growth 
rate that could be restored by adding exogenous α-
KG (Seltzer et al., 2010). 2-HG inhibits the 
synthesis of glutamate by α-KG-dependent 
branched-chain amino acid aminotransferases 
BCAT1 and BCAT2 and, as a consequence, 
dependence of these cells on glutaminase for 
glutamate and GSH biosynthesis increases. 
Inhibition of GLS with CB-839 made IDH mutant 
cells more susceptible to reactive oxygen species 
(ROS)-induced cell death and radiation. Based on 
these findings, a combination of CB-839, the 
alkylating agent temozolomide and radiation is now 
being tested in patients with IDH1 mutant gliomas 
(McBrayer et al., 2018). ROS generation by 
treatment with oxidizing agents synergized with 
GLS silencing or GLS2 overexpression to suppress 
malignant properties of GBM cells (Martèn-Rufián 
et al., 2014). In IDH wild type GBM cells, 
pharmacological NOTCH pathway blockade 
reduced the levels of GLS mRNA, which was 
reflected in reduced intracellular glutamate 
concentration (Kahlert et al., 2016). MiRNAs also 
play an important role in glutamine metabolism of 
glioblastoma. Thus, MIR153 has been found to be 
downregulated in glioblastoma and its 
overexpression inhibits cell growth and promotes 
apoptosis by directly targeting GLS expression (Liu 
et al., 2017). Compensatory anaplerotic 
mechanisms have also been described in GBM. In 
those that use glutamine as the preferred anaplerotic 
precursor, inhibition of GLS is accompanied by 
augmented activity of pyruvate carboxylase to 
stimulate glycolytic metabolism (Cheng et al., 
2011). Conversely, glioblastoma cells respond to 
deficit in glycolysis after mTOR inhibition by 
increasing glutamine metabolism through elevated 
GLS expression. Combination of MTOR and GLS 
inhibition caused suppression of tumor growth in 
vivo (Tanaka et al., 2015). 
Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is one of the most 
aggressive cancers. A high correlation between 
growth rate and dedifferentiation of rat hepatomas 
and GLS activity was already described 50 years 
ago (Linder-Horowitz et al., 1969). In a recent 
study, a large set of clinical samples of HCC and 
normal liver was analysed and GLS was found to 
be highly expressed in tumor samples, whereas 
GLS2 was preferentially expressed in normal cells. 
During malignant progression, a switch from GLS2 
to GLS was observed. High GLS and/or low GLS2 
expression in HCC determined poor prognosis in 
patients with this tumor (Yu et al., 2015). Several 
mechanisms that regulate GLS expression in HCC 
have been described. Wnt/β-catenin pathway, 
associated to HCC stemness, promotes GLS 
expression. After treatment with an agonist of 
Wnt/β-catenin pathway, both GLS mRNA and 
protein increased. In addition, the increase in ROS 
caused by treatment with compound 968 decreased 
the amount of nuclear β-catenin ( CTNNB1) and 
subsequently inhibited expression of target genes 
implicated in HCC stemness (Li et al., 2019). 
RELA also controls GLS expression in HCC and its 
inactivation reduced GLS mRNA levels. 
Dysregulation of RELA and GLS correlated with 
poor prognosis in HCC patients (Dong et al., 2018). 
HCC cells with a mesenchymal phenotype showed 
higher levels of TGF-β than their epithelial 
counterparts, and this resulted in increased GLS 
expression and glutamine anaplerosis (Soukupova 
et al., 2017). A lncRNA that participates in HCC 
progression, HOXA distal transcript antisense RNA 
( HOTTIP), is negatively regulated by MIR192 and 
MIR204 and this regulation modulates GLS 
expression. Inhibition of HOTTIP by siRNA or by 
ectopic expression of miR-192/-204 suppressed 
GLS expression and hence HCC proliferation (Ge 
et al., 2015). A therapeutic strategy combining GLS 
inhibition with ROS induction has been tested in 
HCC cells. Treatment with compound 968 and 
dihydroartemisinin (an anti-cancer drug that 
enhances ROS production) synergistically 
sensitized HCC cells to ROS-induced cytotoxicity 
resulting in apoptosis (Wang et al., 2016). 
Leukemia 
In a study with leukemia cells from medullar blood 
of human patients, both GLS and GLS2 isoforms 
were expressed, although GLS accounted for the 
majority of glutaminase activity in these cells. 
Furthermore, GLS expression was positively 
correlated with the rate of proliferation (Pérez-
Gómez et al., 2005). Acute myeloid leukemia 
(AML) cells that harbour IDH mutations are 
glutamine addicted and their growth could be 
suppressed by treatment with BPTES (Emadi et al., 
2014). Analysis of AML cell lines showed high 
levels of GAC, while KGA was expressed at low 
level. Inhibition of GLS with BPTES or CB-839 
caused reduction of key metabolites downstream of 
glutamate, including TCA cycle intermediates and 
GSH. CB-839 exposure also reduced levels of 
oncometabolite 2-HG and this reduction associated 






Atlas Genet Cytogenet Oncol Haematol. 2019; 23(9) 263 
 
with signs of differentiation (Matre et al., 2016). 
Combined therapy with GLS inhibitors 
dramatically reduced proliferation in AML models. 
Thus, GAC inhibition by CB-839 sinergized with 
BCL2 (B-Cell Leukemia/Lymphoma 2) (Jacque et 
al., 2015) or FLT3 (FMS-like tyrosine kinase 3) 
inhibition (Gregory et al., 2018) to induce loss of 
viability through apoptotic cell death. Synergistic 
antileukemic effects were also observed after 
treatment with BPTES in combination with 
NOTCH1 inhibition (Herranz et al., 2015). 
MiRNAs have also been implicated in glutamine 
metabolism in leukemic cells. Thus, an increase in 
expression and translocation of RELA to the 
nucleus was observed in leukemic Jurkat T cells 
growing in medium with glutamine, which caused a 
higher NF-kB activity. Activation of RELA 
reduced MIR23A expression, leading to a higher 
expression of GLS. Overexpression of MIR23A in 
these cells impaired glutamine metabolism and 
caused mitochondrial dysfunction and cell death 
(Rathore et al., 2012). 
Lung cancer 
GAC is the predominant GLS isoform in 
glutamine-dependent non-small cell lung cancer 
(NSCLC). The increased GAC:KGA ratio observed 
in these cells, compared with normal lung tissue, 
was due to a significant decrease of KGA 
expression in tumoral cells. GAC knockdown in 
glutamine-dependent cells strongly reduced cell 
growth, whereas the effect of KGA knockdown was 
much less pronounced, suggesting that GAC is the 
more essential GLS isoform in these cells (van den 
Heuvel et al., 2012). GAC protein levels were 
similar between tumor and normal tissues: the high 
glutaminase activity in NSCLC cells resulted from 
GAC phosphorylation (Han et al., 2018). However, 
other authors have found that GLS expression is 
significantly higher in NSCLC than in cells from 
normal lung tissues (Lee JS et al., 2016b). A 2-fold 
increase in GAC levels and a reduction in KGA and 
pyruvate carboxylase levels were observed in 
NSCLC cells that underwent ephitelial to 
mesenchymal transition induced by TGF-β, making 
these cells more susceptible to GLS inhibition, as 
shown by impaired TCA cycle anaplerosis and 
increased sensitivity to oxidative stress after 
treatment with BPTES (Ulanet et al., 2014). 
Synergic treatments that combine inhibition of GLS 
and other drug targets have been described in recent 
studies. Thus, treatment with GLS inhibitor 
compound 968 sensitized lung cancer cells to 
apigenin-mediated apoptosis (Lee YM et al., 
2016c). Dual treatment with GLS inhibitor BPTES 
and thymidylate synthase inhibitor 5-fluorouracil 
resulted in the reversal of NSCLC in a preclinical 
xenograft model (Lee JS et al., 2016b). In 
epidermal growth factor receptor ( EGFR) mutant 
lung cancer cells, targeted inhibition of EGFR 
signaling and GLS with erlotinib and CB-839, 
respectively, induced a reduction in glucose and 
glutamine transporters levels and led to tumor 
regression in xenograft models (Momcilovic et al., 
2017). Unfortunately, acquired resistance is 
developed by patients with NSCLC after several 
months of treatment with erlotinib. Compound 968, 
when combined with erlotinib, inhibited the 
proliferation of erlotinib-resistant NSCLC cells by 
decreasing the expression of EGFR (Xie et al., 
2016). The adquired resistance of lung squamous 
cell carcinomas to MTOR inhibition via enhanced 
glutaminolysis was overcome by treatment with 
CB-839 (Momcilovic et al., 2018). 
Melanoma 
Two miRNAs targeting GLS have been found to be 
downregulated in melanoma cells and their low 
levels associated with poor prognosis. When 
overexpressed, both miRNAs (MIR137 and 
MIR203) suppressed glutamine catabolism and 
proliferation of melanoma cells (Chang et al., 2016; 
Luan et al., 2018). MiRNA203 also sensitized 
resistant melanoma cells to temozolomide (Chang 
et al., 2016). 
Ovarian cancer 
Patients with ovarian cancer who initially respond 
to platinum and taxane-based chemotherapy will 
develop drug resistance. Compared to sensitive 
cells, cisplatin-resistant cells showed glutamine 
dependence, associated with the upregulated 
expression of glutamine transporter SLC1A5 
(ASCT2) and GLS mediated by higher levels of 
MYC. GLS overexpression in cisplatin-sensitive 
cells resulted in increased resistance to this agent. 
Conversely, knockdown of GLS re-sensitized 
resistant cells to cisplatin. Combination of BPTES 
and cisplatin synergistically increased apoptosis 
(Hudson et al., 2016). A similar effect on cell 
proliferation was obtained after treatment of 
ovarian cancer cells with paclitaxel and compound 
968. This GLS inhibitor induced cell cycle arrest 
and apoptosis, and sensitized cells to paclitaxel 
(Yuan et al, 2016). Moreover, knockdown of both 
GLS isoforms by siRNA sensitized cells to 
chemotherapy more effectively than depletion of 
GAC or KGA alone (Masamha and LaFontaine, 
2018). Another proposed therapeutic strategy 
combined inhibition of PI3K/Akt/mTOR axis 
(frequently activated in ovarian cancer cells) and 
GLS with PP242 (an inhibitor of mTORC1 and 
mTORC2) and CB-839, respectively. GLS 
inhibition resulted in a dramatic induction of 
PP242-mediated cell death not only by a reduced 
glutamine anaplerosis, but also by a decreased level 
of phosphorylated STAT3 (signal transducer and 
activator of transcription 3) (Guo et al., 2016). 
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Prostate cancer 
GLS is highly expressed in prostate cancers and 
positively correlates with tumor state and 
progression. In glutamine addicted prostate cancer 
cells, GLS regulates glucose uptake through 
inhibition of thioredoxin-interacting protein ( 
TXNIP) expression, a potent negative regulator of 
aerobic glycolisis and glucose uptake. When GLS 
activity was suppressed by siRNA or BPTES, 
TXNIP was remarkably induced and the invasive 
capacity of these cells significantly reduced (Pan et 
al., 2015). It was in these tumors that MYC, which 
contributes to their initiation and progression (Koh 
et al., 2010), was described to upregulate GLS 
expression through suppression of MIR-23a/b (Gao 
et al., 2009). Recent results show that GLS is highly 
expressed in large extracellular vesicles (LEVs) 
extruded from prostate cancer cells (Minciacchi et 
al., 2015). Release of these vesicles is dependent on 
glutamine metabolism. Thus, a significant reduction 
in the production of LEVs is observed when these 
cells are treated with BPTES (Dorai et al., 2018). 
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